

Ryah Medtech Inc

09:26 29 Oct 2019

RYAH Medtech forges research partnership with top Pharma and Oncology player

RYAH Medtech Inc, the medical cannabis and data company, has cemented a deal with a leading pharmaceutical clinic to kick off a research program that will use its dose-measuring vaporizers and dry herb cartridges.

Under the deal's terms, the undisclosed oncology clinic will analyze the safety of using cannabis and hemp to treat patients in chronic pain, using RYAH's proprietary devices which allow medical cannabis patients to precisely control dosage and temperature. The clinic has agreed to purchase about 100,000 RYAH dose-measuring dry herb vaporizers and several million dry herb cartridges over five years, starting in December.

"[By] using our best-in-class vaporizers, cartridges and customized software capabilities, the Clinic will capture medically-relevant seed-to-consumption data on its cannabis-based treatments, which will then be analyzed to assess the safety and efficacy of medical cannabis, with the goal of advancing evidence-based policy making," said Gregory Wagner, RYAH's CEO.

READ: RYAH MedTech signs distribution agreement with Australian medical cannabis producer Cannatrek

The new study will include precision dosing and also pave the way for the clinic to track how patients are responding to treatments, with the help of RYAH's tech.

RYAH, which is headquartered in New York City, will be introducing a customized mobile application and a bit of back-end software for the trial - which will be designed to control temperatures and dosing with precision and direct patient feedback to the clinic.

RYAH uses cartridges pre-filled with either dry herb or concentrate. Users simply scan the cartridge's QR code, set their parameters and RYAH tracks exactly how much vapor has been inhaled.

The Ryah vaporizer is capable of storing results from vaping sessions to create a picture for doctors and patients of how vaping is working for them and what tweaks — such as cannabis strain, dosage level, frequency or temperature — may need to be made.

"Our vaporizers are smart devices that allow patients to set limits on how much they inhale, track their usage in real time, record how they feel after each session and review their stats over time," explains Jordan Medley, RYAH's director of product operations.

News of RYAH's latest tie-up comes on the heels of its move to set up shop Down Under by striking a distribution agreement with Cannatrek Medical Pty Ltd, a licensed medical cannabis company in Australia.

The deal will see RYAH provide its signature dose-measuring dry herb vaporizers and cartridges to Cannatrek, which will fill them with its proprietary strains and distribute them to patients.

Share Information

Code: RYAH
Listing: PRIVATE-NA
Sector: Cannabis
Website: us.ryah.com

Company Synopsis:

*RYAH is the first vaporizer that lets users track and control how much they inhale, ensuring consistent, predictable results. It offers accurate temperature and dosing control down to the millileter. *

*The device tracks the effects of each session and uses artificial intelligence to help select the best strain of cannabis for any patient's symptoms. *

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Ryah Medtech Inc named herein, including the promotion by the Company of Ryah Medtech Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).